AGN 232411Alternative Names: AGN232411
Latest Information Update: 25 Jul 2016
At a glance
- Originator Allergan
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dry eyes
Most Recent Events
- 31 Mar 2016 Allergan completes a phase I trial in Healthy volunteers and in Dry eyes in USA (NCT02420730)
- 01 Jun 2015 Phase-I clinical trials in Dry eyes in USA (Ophthalmic) (NCT02420730)
- 22 Apr 2015 Allergan plans a phase I trial in Healthy volunteers and in Dry eyes in USA (NCT02420730)